Compare DexCom, Inc. (DXCM) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Western Alliance Bancorporation — how do they compare? DexCom, Inc. trades at $89.53 (market cap $33.08B), while Western Alliance Bancorporation trades at $81.46 (market cap $8.78B). The key difference: DexCom, Inc. is far larger — about 3.8× Western Alliance Bancorporation's market cap, and Western Alliance Bancorporation pays a 2.09% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | WAL | |
|---|---|---|
Market Cap | $33.08B | $8.78B |
Sector | Health | Financials |
52-Week High | $89.53 | $96.08 |
52-Week Low | $54.84 | $66.70 |
Enterprise Value | $32.53B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.75, up 2.08% today and near its 52-week high. The stock shows bullish technical momentum with strong earnings beats in recent quarters, including Q2 2026 EPS of $0.70 versus $0.61 expected. Revenue growth accelerated to 13% year-over-year in Q2 2026, driven by G7 system adoption and international expansion. Cash flow from operations improved to $1.44 billion in 2025, supporting financial flexibility.
Outlook remains positive with raised FY2026 guidance and 80% analyst buy ratings, though valuation multiples like P/E of 33.5 suggest premium pricing. Key risks include competitive pressures in glucose monitoring and reliance on reimbursement policies. The consensus price target of $88.65 implies modest upside from current levels.
Western Alliance Bancorporation (WAL) trades at $81.39, up 0.06% on the day, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.08, net income margin of 25.43%, and consistent earnings beats in recent quarters. Recent developments include the launch of WA VenueX, a digital asset liquidity platform, and recognition as Arizona's top bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 15% upside, supported by 79% analyst buy ratings. Risks include negative operating cash flow and institutional selling, but revenue growth and profitability trends provide a solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
